I know that you and others keep indicating that Cytocom is a private company and technically it can be considered as such. HOWEVER, this "private" company became a minority owned subsidiary instead of a majority owned subsidiary due to, as you indicate, dilution as shares in Cytocom were issued for who knows what purposes. But, here is the rub-Cytocom was given the license to the U. S. Patent No. 7,879.870 for the " Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists". This Patent is one of 3 or 4 IMUN Patents with a reasonable life period still in existence and is/was a very valuable asset belonging to IMUN. Now, no one who is a shareholder or anyone with a miniscule amount of intelligent business acumen would not want to know at least what has happened in over FOUR years with a very valuable patent that has underlying positive clinical data in the hands of the FDA and with a Phase 2 level meeting held with the FDA in order to proceed with further clinical studies, expanding upon the clinical data and head to approval to market. This is/was a very valuable asset of the public company IMUN and the Board of Directors and management should be strongly held to account in detail. If you are a shareholder I cannot fathom how you would not want to know what has been done or is being done to further the value of this asset. What happened to the plans for Cytocom that was a majority owned Company and why such significant dilution in IMUN's holdings?
Take a look at the Cytocom website and tell me what progress has been made over FOUR years.
